Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer.

BACKGROUND In May 2006, the UK Human Fertilization and Embryology Authority (HFEA) approved use of preimplantation genetic diagnosis (PGD) for lower penetrance, late onset cancer susceptibility syndromes such as hereditary breast and ovarian cancer (HBOC). This is the first report on views of BRCA gene mutation carriers on use of PGD for HBOC. METHODS Between December 2005 and February 2006, a postal survey of BRCA mutation carriers attending a Familial Cancer Clinic was undertaken. RESULTS Of 102 women sent questionnaires, 52 (51%) responded. Thirty-nine (75%) felt it was acceptable to offer PGD for HBOC. Fifteen (37.5%) of 40 who had completed their families would personally have considered PGD if it had been available. Only one of seven (14%) contemplating a future pregnancy would consider PGD. Eighteen (35%) wrote extensively about their concerns including increasing availability of effective treatment and good quality of life. CONCLUSIONS The majority of BRCA gene mutation carriers are supportive of offering PGD to others, thus endorsing the HFEA decision. However, most women would not consider it personally. Concerns raised highlight the need for regular HFEA reviews of the licensing criteria, as HBOC may cease to be a "serious life threatening illness" in the future.

[1]  R. Catarino,et al.  Ovarian Cancer and Genetic Susceptibility: Association of A61G Polymorphism in the EGF Gene , 2009, Experimental biology and medicine.

[2]  N. Muntjewerff,et al.  ESHRE PGD Consortium data collection V: cycles from January to December 2002 with pregnancy follow-up to October 2003. , 2008, Human reproduction.

[3]  S. Gayther,et al.  Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention , 2006, Acta obstetricia et gynecologica Scandinavica.

[4]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[5]  J. Robertson Extending preimplantation genetic diagnosis: the ethical debate. Ethical issues in new uses of preimplantation genetic diagnosis. , 2003, Human reproduction.

[6]  J. Robertson Extending preimplantation genetic diagnosis: the ethical debate , 2003 .

[7]  A. Veiga,et al.  Preimplantation genetic diagnosis: patients' experiences and attitudes. , 2002, Human reproduction.

[8]  S. Ziebland,et al.  Analysing qualitative data , 2000, BMJ : British Medical Journal.

[9]  A. Ao,et al.  Preimplantation Genetic Diagnosis of Inherited Cancer: Familial Adenomatous Polyposis Coli , 1998, Journal of Assisted Reproduction and Genetics.

[10]  J. M. Green,et al.  Preimplantation diagnosis and other reproductive options: attitudes of male and female carriers of recessive disorders. , 1997, Human reproduction.

[11]  N Mays,et al.  Qualitative Research: Rigour and qualitative research , 1995 .

[12]  C. Moutou,et al.  ESHRE PGD Consortium data collection IV: May-December 2001. , 2005, Human reproduction.

[13]  C. Finck,et al.  Knowledge and attitudes towards preimplantation genetic diagnosis in Germany. , 2005, Human reproduction.

[14]  J. Robertson Ethical issues in new uses of preimplantation genetic diagnosis , 2003 .

[15]  H. M. van der Ploeg,et al.  Attitudes towards reproductive issues and carrier testing among adult patients and parents of children with cystic fibrosis (CF). , 2001, Prenatal Diagnosis.

[16]  S. Ziebland,et al.  qualitative data Qualitative research in health care : Analysing , 1999 .